# A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)

> **NCT00546052** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1738 (actual)

## Conditions studied

- Hypertension
- Metabolic Disorder

## Interventions

- **DRUG:** losartan potassium (+) hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00546052
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-01
- **Primary completion:** 2008-01-01
- **Final completion:** 2008-01-01
- **Target enrollment:** 1738 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546052, "A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00546052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*